CCI registered 54 cases of anti-competitive practices in 2025 (See 'Corp Brief') National Institute of Ayurveda reaffirms role as global centre for education & patient care (See 'Corp Brief') Trade Mark - prior user rights override subsequent registration, particularly where adoption of deceptively similar subsequent trade mark, is not bona fide & is aimed at riding on existing goodwill of existing trade mark: HC (See 'Legal Desk') Electronic Interlocking rolled out at 34 Railway Stations of N-E (See 'Corp Brief') PMLA - Objectives of enacting PMLA 2002, was attachment and confiscation of proceeds of crime which is quintessence so as to combat evil of money-laundering: SAFEMA (See 'Legal Desk') Khelo India Multipurpose Hall at SAI Sambhajinagar is addition to Olympic readiness: MoS (See 'Corp Brief') PM addresses community programme in Kuala Lumpur (See 'Corp Brief') A & C - mandate of arbitrators appointed unilaterally by one party, merits being terminated, where the other party explicitly refuses to waive applicability of Section 12(5) of the Act: HC (See 'Legal Desk') India-US Trade Agreement: Major boost for Textile Industry (See 'Corp Brief') IBC - In unavailability of adequate document/information and considering effect of limitation period, assigning of 'zero' value to trade receivables, without any due justification, is not appropriate: IBBI (See 'Legal Desk') India has signed MoUs with 23 countries for cooperation on Digital Public Infrastructure (See 'Corp Brief') A&C - Once arbitral tribunal has adopted plausible & reasonable interpretation of facts and contractual terms, courts cannot re-appreciate evidence or sit in appeal over award: SC (See 'Legal Desk') Railways inspects All Bridges Twice a Year (See 'Corp Brief') A&C - Permitting a civil suit to challenge an award confirmed by the Supreme Court would undermine the arbitral framework and public confidence in arbitration: HC (See 'Legal Desk') Over 1.25 lakh Livestock Farmers joined Virtual Awareness Program: MoS (See 'Corp Brief') A & C - Referral court not required to conduct detailed or contested inquiry & must limit itself to ascertaining whether underlying contract contains an arbitration clause covering disputes between the parties: HC (See 'Legal Desk') Pariksha Pe Charcha marks First-Ever multi-location nationwide engagement (See 'Corp Brief') SEBI - If Noticee violated regulation 23(1) and 23(4) of LODR Regulations as alleged in SCN, Noticee is liable for payment of monetary penalty in terms of section 15HB of SEBI Act: SEBI (See 'Legal Desk') TRAI issues Telecommunication Services Interconnection Regulations, 2026 (See 'Corp Brief') Trade Marks - Procedural defects & inadvertent errors which are curable should not be permitted to defeat substantive rights, unless shown to be deliberate, mala fide, or prejudicial to opposite party: HC (See 'Legal Desk') The Securities Markets Code, 2025: Strengthened Enforcement, Weakened Accountability? (See 'CORP EINSICHT')

Print

Glenmark's Swiss arm gets nod to market Ryaltris nasal spray in Russia

Published: Feb 22, 2021

By TIOLCORPLAWS News Service

NEW DELHI, FEB 22, 2021: GLENMARK Pharmaceuticals on Monday said its Swiss subsidiary, Glenmark Specialty, has received marketing approval from Russian health regulators for its fixed-dose combination nasal spray, Ryaltris.

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, like stuffy and runny nose, nasal itching, sneezing, as well as irritated eyes, in adults and children over 12 years of age.

"Glenmark has built strong capabilities in the area of respiratory medicine and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," said Csaba Kantor, Senior Vice President - Russia and CIS region, Glenmark.

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent.

"Glenmark has a strong established presence in Russia for over 30 years, which will enable us to lead the commercialization of this product in the country. We look forward to being able to make this innovative product available to patients in Russia as soon as possible," Mr Kantor added.

The company estimated that Ryaltris will be available to patients in Russia by the first quarter of 2021-22.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.